Using Advanced Oxidation Protein Products and Ischaemia-modified Albumin to Monitor Oxidative Stress Levels in Patients with Drug-induced Liver Injury

Overview

Journal Sci Rep

Specialty Science

Date 2020 Oct 23

PMID 33093629

Citations 16

Authors

Lan-Lan Xiao

Fen Zhang

Ya-Lei Zhao

Ling-Jian Zhang

Zhong-Yang Xie

Kai-Zhou Huang

Xiao-Xi Ouyang

Xiao-Xin Wu

Xiao-Wei Xu

Lan-Juan Li

Affiliations

Soon will be listed here.

Abstract

Increased oxidative stress levels play a key role in idiosyncratic drug-induced liver injury (DILI) pathogenesis. To investigated whether advanced oxidation protein products (AOPPs) and ischaemia-modified albumin (IMA) can be used to monitor oxidative stress in DILI patients and to assess disease severity. We performed spectrophotometric assays to assess AOPPs and IMA in 68 DILI patients with severity grade 0-2 (non-severe group), 60 with severity grade 3-5 (severe group), and 38 healthy controls. The results showed that baseline AOPPs and IMA serum levels and AOPPs/albumin and IMA/albumin ratios were significantly higher in DILI patients than in healthy controls. Besides, in comparison to the non-severe group, the severe group showed higher baseline AOPPs and IMA serum levels and AOPPs/albumin and IMA/albumin ratios. AOPPs and IMA serum levels and AOPPs/albumin and IMA/albumin ratios decreased after treatment in both patient groups. Combining the correlation analysis and areas under the receiver operating curve (AUROCs) analysis results, that IMA outperformed to be one is the most reliable marker to assess disease severity of DILI. Our findings indicated that AOPPs and IMA can serve as key biomarkers for monitoring oxidative stress levels in DILI patients and can indicate disease severity. The IMA outperformed to be one of the most reliable oxidative stress biomarkers to assess disease severity of DILI.

Citing Articles

Exploring the mechanism of sesamin for the treatment of PM-induced cardiomyocyte damage based on transcriptomics, network pharmacology and experimental verification.

Zhang Y, Wen R, Ren J, Zhang F, Pei H, Zuo J Front Pharmacol. 2024; 15:1486563.

PMID: 39564108 PMC: 11573564. DOI: 10.3389/fphar.2024.1486563.

Durability and on-treatment predictors of recompensation in entecavir-treated patients with hepatitis B and decompensated cirrhosis.

Deng Y, Kang H, Xiang H, Nan Y, Hu J, Meng Q JHEP Rep. 2024; 6(7):101091.

PMID: 39022388 PMC: 11252528. DOI: 10.1016/j.jhepr.2024.101091.

An auxiliary strategy of partial least squares regression in pharmacokinetic/pharmacodynamic studies: A case of application of guhong injection in myocardial ischemia/reperfusion rats.

Chen H, Li C, Shao C, Wu Y, Wan H, He Y J Food Drug Anal. 2024; 32(1):79-102.

PMID: 38526587 PMC: 10962654. DOI: 10.38212/2224-6614.3492.

Highly oxidized albumin is cleared by liver sinusoidal endothelial cells via the receptors stabilin-1 and -2.

Holte C, Szafranska K, Kruse L, Simon-Santamaria J, Li R, Svistounov D Sci Rep. 2023; 13(1):19121.

PMID: 37926735 PMC: 10625979. DOI: 10.1038/s41598-023-46462-9.

The Role of Mechanistic Biomarkers in Understanding Acetaminophen Hepatotoxicity in Humans.

McGill M Drug Metab Dispos. 2023; 52(8):729-739.

PMID: 37918967 PMC: 11257692. DOI: 10.1124/dmd.123.001281.

References

Stine J, Chalasani N . Chronic liver injury induced by drugs: a systematic review. Liver Int. 2015; 35(11):2343-53. DOI: 10.1111/liv.12958. View

Larrey D . Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002; 22(2):145-55. DOI: 10.1055/s-2002-30105. View

Gomez-Lechon M, Tolosa L, Donato M . Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs. J Appl Toxicol. 2015; 36(6):752-68. DOI: 10.1002/jat.3277. View

Fontana R, Watkins P, Bonkovsky H, Chalasani N, Davern T, Serrano J . Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009; 32(1):55-68. PMC: 3637941. DOI: 10.2165/00002018-200932010-00005. View

Chen C, Tsai W, Lin P, Shiesh S . The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease. Clin Chem Lab Med. 2011; 49(11):1817-21. DOI: 10.1515/CCLM.2011.675. View

Torbitz V, Bochi G, De Carvalho J, de Almeida Vaucher R, da Silva J, Moresco R . In vitro oxidation of fibrinogen promotes functional alterations and formation of advanced oxidation protein products, an inflammation mediator. Inflammation. 2014; 38(3):1201-6. DOI: 10.1007/s10753-014-0085-x. View

Anderstam B, Ann-Christin B, Valli A, Stenvinkel P, Lindholm B, Suliman M . Modification of the oxidative stress biomarker AOPP assay: application in uremic samples. Clin Chim Acta. 2008; 393(2):114-8. DOI: 10.1016/j.cca.2008.03.029. View

Chalasani N, Hayashi P, Bonkovsky H, Navarro V, Lee W, Fontana R . ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014; 109(7):950-66. DOI: 10.1038/ajg.2014.131. View

Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, Nguyen A, Zingraff J, Jungers P . Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996; 49(5):1304-13. DOI: 10.1038/ki.1996.186. View

10.

Ortega-Alonso A, Stephens C, Lucena M, Andrade R . Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. Int J Mol Sci. 2016; 17(5). PMC: 4881536. DOI: 10.3390/ijms17050714. View

11.

Gottlieb M, da Cruz I, Duarte M, Moresco R, Wiehe M, Schwanke C . Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab. 2009; 95(2):586-91. PMC: 2840868. DOI: 10.1210/jc.2009-1592. View

12.

Sun J, Sugiyama A, Masuda A, Ochi T, Takeuchi T . Expressions of protein oxidation markers, dityrosine and advanced oxidation protein products in acetaminophen-induced liver injury in rats. J Vet Med Sci. 2011; 73(9):1185-90. DOI: 10.1292/jvms.11-0088. View

13.

Ellidag H, Eren E, Yilmaz N, Cekin Y . Oxidative stress and ischemia-modified albumin in chronic ischemic heart failure. Redox Rep. 2014; 19(3):118-23. PMC: 6837664. DOI: 10.1179/1351000213Y.0000000083. View

14.

Zhao Y, Zhang L, Ouyang X, Jiang Z, Xie Z, Fan L . Advanced oxidation protein products play critical roles in liver diseases. Eur J Clin Invest. 2019; 49(6):e13098. DOI: 10.1111/eci.13098. View

15.

Aleo M, Luo Y, Swiss R, Bonin P, Potter D, Will Y . Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology. 2014; 60(3):1015-22. DOI: 10.1002/hep.27206. View

16.

Ding R, Jiang H, Sun B, Wu X, Li W, Zhu S . Advanced oxidation protein products sensitized the transient receptor potential vanilloid 1 via NADPH oxidase 1 and 4 to cause mechanical hyperalgesia. Redox Biol. 2016; 10:1-11. PMC: 5037245. DOI: 10.1016/j.redox.2016.09.004. View

17.

Senior J . Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther. 2012; 92(3):332-9. DOI: 10.1038/clpt.2012.108. View

18.

Li L, Jiang W, Wang J . Clinical analysis of 275 cases of acute drug-induced liver disease. Front Med China. 2014; 1(1):58-61. DOI: 10.1007/s11684-007-0012-8. View

19.

Borrelli A, Bonelli P, Tuccillo F, Goldfine I, Evans J, Buonaguro F . Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biol. 2018; 15:467-479. PMC: 5975181. DOI: 10.1016/j.redox.2018.01.009. View

20.

Will Y, Dykens J . Mitochondrial toxicity assessment in industry--a decade of technology development and insight. Expert Opin Drug Metab Toxicol. 2014; 10(8):1061-7. DOI: 10.1517/17425255.2014.939628. View